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ABSTRACT
Multiple endocrine neoplasia type 1 (MEN 1) is an autosomal
dominant disease characterized by neoplasia of the parathyroid
glands, the endocrine pancreas, and the anterior pituitary gland. In
addition, families with isolated endocrine neoplasia, notably familial
isolated hyperparathyroidism (FIHP) and familial acromegaly, have
also been reported. However, whether these families constitute MEN
1 variants or separate entities remains speculative as the genetic
bases for these diseases are unclear. The gene for MEN 1 has recently
been cloned and characterized. Using single strand conformation
analysis (SSCA) and sequencing, we performed mutation analysis in:
a) a total of 55 MEN 1 families from 7 countries, b) 13 isolated MEN
1 cases without family history of the disease, c) 8 acromegaly families,
and d) 4 FIHP families. Mutations were identified in 27 MEN 1
families and 9 isolated cases. The 22 different mutations spread
across most of the 9 translated exons and included frameshift (11),
nonsense (6), splice (2), missense mutations (2), and in-frame dele-
tions (1). Among the 19 Finnish MEN 1 probands, a 1466del12 mu-
tation was identified in 6 families with identical 11q13 haplotypes and
in 2 isolated cases indicating a common founder. One frameshift
mutation caused by 359del4 (GTCT) was found in 1 isolated case and
4 kindreds of different origin and haplotypes; this mutation therefore
represents a common “warm” spot in the MEN1 gene. By analyzing
the DNA of the parents of an isolated case one mutation was con-
firmed to be de novo. No mutation was found in any of the acromegaly
and small FIHP families, suggesting that genetic defects other than
the MEN1 gene might be involved and that additional such families
need to be analyzed. (J Clin Endocrinol Metab 83: 2621–2626, 1998)
MULTIPLE endocrine neoplasia type 1 (MEN1)(OMIM*131100) is one of the familial cancer syn-
dromes transmitted as an autosomal dominant trait with
over 95% penetrance and an equal sex distribution. It is
characterized by neoplasia of the parathyroids (90–97% of
patients), the endocrine pancreas (30–80%), and the anterior
pituitary (15–50%) (1). The patients may have only one type
of gland involved or any combination, but in addition may
have other less frequently associated features such as lipo-
mas, carcinoids, and adrenocortical neoplasia. Although the
majority of known MEN 1 families are of Caucasian origin,
MEN 1 families of other ethnic groups have been described
(2, 3). Recently, the MEN1 gene, which was mapped to chro-
mosomal region 11q13 (4), was identified by positional clon-
ing (5, 6). It contains 1 untranslated exon and 9 coding exons
that encode a 610-amino acid protein. As it has no homology
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to previously known proteins, its function remains un-
known. Mutation analysis in MEN 1 patients identified mu-
tations in all of the 9 coding exons, but no genotype-pheno-
type correlation was established (7).
A number of reported kindreds with familial endocrine
disorder, notably familial isolated hyperparathyroidism
(FIHP) and familial pituitary tumors, had been considered as
variants of MEN 1. Some of these families were found to be
linked to the MEN1 locus, while some were excluded. To
date, all FIHP families tested genetically were assigned to the
loci of either MEN 1 (8) or the hyperparathyroidism-jaw-
tumor syndrome (HP-JT), which was mapped to chromo-
some 1q21-q32 (9, 10). In the case of familial pituitary tumors,
the majority of reported families were mainly characterized
by familial acromegaly. In these families the mode of trans-
mission was considered as autosomal dominant, and re-
duced penetrance was frequently found. In addition, the
families were usually small compared with those of classical
MEN 1, and a number of them also had additional endocrine
lesions (11, 12). To date, linkage to MEN1 has been excluded
in two kindreds but no new locus has been assigned (11, 12).
However, in one Japanese family with 3 affected members,
linkage to MEN1 could not be excluded, and loss of het-
erozygosity of the “wild-type” alleles was found in two tu-
mors from the two brothers (13).
The present mutation screening was undertaken to further
elucidate the repertoire of mutations in MEN 1 patients and
its possible role in FIHP and familial acromegaly.
Subjects, Materials, and Methods
Families
Informed consent was obtained from all patients, and the study was
approved by the local Ethical Committees of each participating hospital.
The diagnosis of MEN 1 was based on the finding of neoplasia in 2 or
more principal MEN 1-related glands i.e. parathyroid, endocrine pan-
creas, and anterior pituitary. In familial MEN 1, 1 member fulfilling the
criteria for MEN 1 and 1 first degree relative with 1 feature had to be
found in a kindred. A de novo germline mutation was considered in an
individual with clinical features of MEN 1, who had a negative family
history including exclusion of the disease in both parents. We performed
mutation analysis on a total of 55 MEN 1 families from 7 countries: 16
Finnish, 19 Swedish, 13 Australian, 2 Malaysian (Chinese/Mongolian
descent), 3 North American, 1 Italian, and 1 Iranian. The results from 2
of the families (Swe 1–40 and Swe 1–43) have been published previously
(6). In addition, we also studied 13 isolated cases with no family history
of MEN 1.
Four FIHP families in which linkage to the MEN1 gene could not be
excluded by haplotyping or lod score analysis, were included in the
present studies. Clinically, these were families with two or more mem-
bers with primary hyperparathyroidism: one family with four affected
cases including a pair of identical twins, one with three cases, and two
with two cases. In all cases, multiglandular disease was found, and
familial benign hypocalciuric hypercalcemia was excluded by biochem-
ical screening including urine calcium. Families that were linked to the
HPT-JT (HRPT2) locus in 1q (10) were not included in the analysis.
The eight acromegaly families comprised seven acromegaly-only
families and one family with two cases of acromegaly, one primary
hyperparathyroidism, and one prolactinoma (12). One of the acromeg-
aly-only families was the largest reported family, with five affected cases
(14). Five other families have not been reported: one with three affected
(see Fig. 3 below) and four with two affected members. Family members
from these families had been investigated vigorously for MEN 1 and,
except for growth-hormone secreting pituitary tumors, no evidence of
other endocrinopathies could be found.
Single-Strand Conformation Analysis (SSCA)
Genomic DNA was extracted from peripheral blood samples using
standard methods. The 9 translated exons of the gene were amplified as
15 different fragments of 200–300 bp each, as previously described (6).
Genomic DNA (50 ng) was amplified using standard PCR conditions in
50 mm KCl, 10 mm Tris-HCl, pH 9.0, 1.5 mm MgCl2 (Promega, Madison,
WI), 0.2 mm dTTP, dCTP, and dGTP, 0.05 mm dATP, and [a-32P]-dATP
(NEN, Boston, MA) at 1 mCi/reaction and 2 U Taq DNA polymerase
(Promega) in a final volume of 15 mL. Thermocycling conditions con-
sisted of 30 cycles of 1 min at 94 C, 1 min at 62 C, and 1 min at 72 C,
followed by one cycle of 5 min extension at 72 C. The PCR products were
then electrophoresed in 25% MDE (FMC, ME) gels at room temperature
for 12 h at 6–8 W. Gels were dried before autoradiography was carried
out.
Direct DNA sequencing
Three acromegaly families were fully sequenced. The rest were stud-
ied by SSCA followed by sequencing of the shifted bands. All SSCA
shifted bands were excised from the MDE gel and placed in 50 mL of H2O
at 37 C for 1 h. A 5 mL aliquot of this solution was then amplified in a
50 mL reaction with the following components: 50 mm KCl, 10 mm
Tris-HCl, pH 9.0, 1.5 mm MgCl2(Promega), 0.2 mm dTTP, dCTP, dGTP,
and dATP, and 1.5 U of Taq DNA polymerase (Promega). The purified
PCR products were sequenced from both strands. For sequence reac-
tions, one of the PCR primers was biotinylated at the 59 end. Solid phase
sequence reactions with 35S9-labeled dATP were performed using Dyna-
beads (Dynal, Chantilly, VA) and Sequenase (USB, Cleveland, OH)
according to the manufacturer’s manuals, followed by Terminal De-
oxynucleotidyl Transferase (Boehringer Mannheim, Indianapolis, IN)
treatment for 15 minutes with the addition of 0.2 mm dNTP’s. Sequence
reactions were then run on 6% denaturing polyacrylamide gels and
autoradiographed overnight. Confirmation of mutation was carried out
in the families to demonstrate segregation of the mutation with the
disease. In cases where the mutation created or eliminated a restriction
site, restriction cleavage was carried out in the family members. In the
cases where the mutation did not affect a restriction site, the mutation
was sequenced in affected and unaffected family members. Missense
mutations were sought in 100 unaffected individuals.
Genotyping and linkage analysis. Five polymorphic microsatellite markers
close to and flanking MEN1 were selected (15): D11S480, PYGM,
D11S449, D11S4155, and D11S913. The members of the Norwegian ped-
igree were also genotyped with two additional markers D1S1679 and
D18S976 to confirm parenthood. PCR reactions were performed in a total
volume of 10 mL containing 50–100 ng of genomic DNA, 50 mm KCl, 10
mm Tris-HCl (pH 8.3), 1.5 mm MgCl2, 125 mm of each dNTP, 2 pmol of
each oligodeoxynucleotide primer (one of which was end-labeled with
[g32P]-dATP), and 0.2 U DNA polymerase (Dynazyme, Finnzyme Oy,
Finland). Samples were amplified using a hot-start of 5 min at 94 C,
followed by 25 cycles of denaturing at 94 C for 30 sec, annealing at 55
C for 30 sec, and elongation at 72 C for 30 sec, and a final elongation step
at 72 C for 7 min. Polyacrylamide gel electrophoresis was carried out on
the PCR products followed by either autoradiography or Bio-imaging
analysis (Bas 1000, Fuji, Japan). Haplotypes were then constructed.
Two point lod scores were calculated for the acromegly family of
Kadazan origin using LINKAGE package 5.1 (15a). Using a conservative
approach, cases III-1, 2, and 6 were labeled as affected, while all unaf-
fected cases were considered as unknown. Familial acromegaly was
modeled as a rare autosomal dominant disease with a reduced pen-
etrance (50%). Allele frequencies were set at equal levels.
Results
A total of 22 different mutations (Figs. 1 and 2) were
identified in 27 MEN 1 families (51%) and 9 isolated cases
(69%). These different mutations consisted of 11 frameshift,
6 nonsense, 2 splicing, 2 missense mutations, and 1 in-frame
deletion (Table 1). Five mutations occured in more than 1
proband: 359del4 in 5, 738del4 in 2, W341X in 2, 1466del12
in 8, and 1657insC in 2.
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Five common polymorphisms were also detected in 12
MEN 1 families: S145S, R171Q, G214G, D418D, and A541T.
In the 19 Finnish MEN 1 probands, only 2 mutations were
found: D418N in 1 family and 1466del12 in 6 families and 2
isolated cases. The 6 families shared the same MEN 1-linked
marker haplotypes (data not shown). No mutation was
found in 10 other Finnish families. One Norwegian isolated
MEN 1 case without family history of the disease had pri-
mary hyperparathyroidism, gastrinoma, and benign adre-
nocortical tumors, and showed a 597delG mutation (Fig. 3).
This mutation was not present in either of his parents nor in
his sister, who were all normal on clinical and biochemical
examination. Parenthood was confirmed by typing of 6 mi-
crosatellite markers from chromosomes 1, 11, and 18. The
results for the 4 markers in 11q13 are shown in Fig. 3. The
MEN1 mutation was transmitted to 2 of the children, com-
firming that the patient carries a de novo germline MEN1
mutation. These 2 children are in their teens, and clinical
evidence of primary hyperparathyroidism was subsequently
found in the older sister (III-2 Fig. 3), while the younger sister
is still disease free.
No mutation was identified in any of the four FIHP and
eight acromegaly families. One acromegaly family in which
MEN 1 could not be excluded by haplotyping or linkage
analysis is shown in Fig. 4. Maxiumum lod scores of 0.86 at
u 5 0.0 were obtained with the markers PYGM and
D11S4155. However no MEN1 mutation was found in this
family neither by SSCA screening or full sequencing.
Discussion
Overall, we only detected mutations in about 55% of all
cases, compared with a previous report which detected over
90% of mutations in their families by using dideoxy finger
printing (ddf) (7). This discrepancy could be related to the
difference in sensitivity of both methods. We employed the
more common method of SSCA, which usually has a detec-
tion rate of approximately 50–70%. Also, the disrepancy in
the present study might reflect the difference in patient ma-
terial. It is possible that some of the mutations might occur
in untranscribed or regulatory regions.
We identified 22 different mutations in 27 MEN 1 families
and 9 isolated cases. In agreement with previous reports, the
majority of these mutations were frameshift or nonsense,
which would eliminate the functions of one copy of the gene.
These results, together with the findings of inactivating mu-
tations in endocrine tumors that showed LOH of 11q13 (16,
17), support Knudson’s two-hits mutation theory of a tumor
suppressor gene (18). In the future, it will be interesting to see
how the function of the gene, which will come to light in due
course, fits in with this theory. The present study also extends
the spectrum of mutations in the MEN1 gene, which spread
across most of the translated exons. This wide spectrum of
mutations, together with the vast intra- and interfamilial
phenotypic variations, implies difficulties in genotype-phe-
notype correlation. Recently, we identified a number of fam-
ilies with clusterings of thymic carcinoids, uncommon but
malignant tumors of which a quarter were associated with
MEN 1 (19, 20). Mutation analysis in these families confirmed
different germ-line mutations in different exons of the gene
(20). In the study of the kindreds with the prolactinoma
variant, which is considered a distinct MEN 1 phenotype
MEN1Burin, three different genotypes were found. Two mu-
FIG. 1. Diagramatic representation of the mutations found in the MEN1 gene. The first exon is not transcribed. The numbers in brackets
represent the number of unrelated MEN 1 patients with the same mutation.
FIG. 2. Examples of MEN1 mutation detection in three familial MEN
1 cases. Left: SSCA shifts detected in exon 2 in families 1–25 and 1–27
are shown to be a 4 bp deletion by separating the PCR products in
sequencing gels, and the mutation is then identified as a 359del4
framshift by direct sequencing. To the right is shown an SSCA shift
in exon 3 detected in family 1–20 and confirmed to be a nonsense
W220X mutation by direct sequencing.
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tations were in different exons and one not detected, thus
excluding any genotype-phenotype correlation (7).
Mutations were also found in 9 of 13 isolated cases in
which no family history of MEN 1 could be found. This rate
of mutation detection made mutation analysis of the MEN1
gene worthwhile in isolated cases. All isolated cases had 2 or
more of the MEN 1-related features. In one case, in which the
DNA of both parents were available, we confirmed that it
was a de novo mutation (Fig. 2). In addition, we also found
a common mutation, 359del 4 (GTCT) in 5 probands: 2 Swed-
ish, 1 Australian, and 1 Malaysian family of Chinese origin,
and 1 isolated case from Australia. Except the 2 Swedish
families, which shared the same 11q13 haplotype, the others
were found to have different haplotypes. This mutation was
also reported in a French family (6), suggesting the existence
of a mutation “warm spot”. Clinically, there was no salient
feature in these families that distinguished them from other
MEN 1 families.
Founder effect is well-known in a number of hereditary
diseases found in isolated populations. In the Finnish pop-
ulation, which is only 80–100 generations old, some 30 dis-
eases have been reported to be more prevalent than in other
populations (21), and identification of some of these genes
has shown the existence of common founders (22). As MEN
1 is not more prevalent in the Finnish population, it is ex-
FIG. 3. A Norwegian MEN 1 patient carrying a de novo mutation,
597delG, which is not present in either parent or his sister, all of whom
are clinically normal. The transmission of the mutation to his two chil-
dren is compatible with that of the segregating haplotype (hatched).
TABLE 1. MEN1 mutations in 27 familial and 9 isolated MEN 1 cases
Pedigree Country Exon Mutation Amino acid
2–16 # Sweden 2 311insG Frameshift
1–25 Malaysia 2 359del4(GTCT) Frameshift, 32 missense aa stop
2–45 # Australia 2 359del4(GTCT) Frameshift, 32 missense aa stop
1–27 Australia 2 359del4(GTCT) Frameshift, 32 missense aa stop
1–42 Sweden 2 359del4(GTCT) Frameshift, 32 missense aa stop
1–43 Sweden 2 359del4(GTCT) Frameshift, 32 missense aa stop
1–40 Sweden 2 R98X Stop
2–6 # USA 2 416delC Frameshift
2–26 # Sweden 3 560insA Frameshift
2–24 Sweden 3 A160T Missense, ala to thr
1–48 # Norway 3 597delG Frameshift
1–29 Australia 3 599insA Frameshift
1–31 Australia 3 E191X Stop
2–18 # Sweden 3 734delC Frameshift
2–34 Italy 3 738del4(ACAG) Frameshift
2–20 # Sweden 3 738del4(ACAG) Frameshift
1–19 Australia 3 IVS3 1 1 (G-T) Splicing
1–20 Australia 4 W220X Stop
1–44 Sweden 4 Y227X Stop
1–35 Australia 4 IVS4 1 1(G-T) Splicing
2–36 Sweden 7 1089delT Frameshift
1–46 Sweden 7 W341X Stop
1–50 Sweden 7 W341X Stop
1–8 Finland 9 D418N Missense, asp to asn
1–30 Australia 9 1452del11(GAGGGACAG/GT) Frameshift
1–3 Finland 10 1466del12(GCAGAAGGTGCG) Loss of 3 aa
1–6 Finland 10 1466del12(GCAGAAGGTGCG) Loss of 3 aa
1–7 Finland 10 1466del12(GCAGAAGGTGCG) Loss of 3 aa
1–11 # Finland 10 1466del12(GCAGAAGGTGCG) Loss of 3 aa
1–12 Finland 10 1466del12(GCAGAAGGTGCG) Loss of 3 aa
1–16 # Finland 10 1466del12(GCAGAAGGTGCG) Loss of 3 aa
1–17 Finland 10 1466del12(GCAGAAGGTGCG) Loss of 3 aa
1–51 Finland 10 1466del12(GCAGAAGGTGCG) Loss of 3 aa
1–26 Australia 10 1657insC Frameshift
1–34 Australia 10 1657insC Frameshift
2–30 Sweden 10 R527X Stop
#, Isolated case; aa, amino acid.
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pected that new mutation rate would be similar or close to
that of other populations. Here we found 2 novel different
mutations in the MEN 1 kindreds: 1466del12 and D418N. At
least one or more unknown mutations exist since, in 10 other
cases, no mutations were identified. The 1466del12 mutation
occured in 6 kindreds that shared a common 11q13 haplo-
type, thus pointing to a common founder in these families.
The 9 familial and 1 isolated MEN 1 cases from Finland in
which no mutation was detected do not share one common
11q13 haplotype and thus are not expected to have one
founder mutation (23).
In agreement with previous studies (7), we did not find
mutation in any of the FIHP families. These families were
small or incomplete in sampling, thus haplotyping or lod
score analysis were inconclusive. It is more likely that a
separate gene, for example the one responsible for HPT-JT
(yet to be cloned) was involved. It will be interesting to
analyze some of the large FIHP families that were assigned
to MEN1 (8).
As in FIHP families, we did not detect any mutation in the
acromegaly families. In one family that had been excluded
from MEN1 by linkage analysis (12), it was not so surprising
not to find mutation in the MEN1 gene. However, one other
family, shown in Fig. 4, was possibly linked to MEN1. Two
siblings and one cousin developed acromegaly associated
with growth hormone-secreting tumors. However, none of
their parents had any feature of acromegaly, and all bio-
chemical investigations in them were normal. It is possible
that the mutations in all these families were unique and lay
in regulatory or untranscribed regions of the MEN1 gene.
More likely, different genetic defects other than those of the
MEN1 gene might be responsible. A number of genes in-
cluding G-proteins, Rb adenyl cyclase, and GHRH-receptor
have been implicated in the pathogenesis of pituitary disease
(24). It will be interesting to study the roles of these genes in
these families.
In conclusion, germline mutations of the MEN1 gene are
responsible for the hereditary state of MEN 1, while a num-
ber of them most probably represent de novo mutation pa-
tients without a family history of the disease. Further char-
acterization of the MEN1 mutations in parallel with
functional studies, would elucidate its role both in physio-
logical and pathological states.
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